Loading stock data…
$7.50+0.10 (+1.35%)
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States.
Phathom Pharmaceuticals, Inc. in the Healthcare sector is trading at $7.50 with a market capitalization of $607M. Wall Street consensus targets $20.09 (11 analysts), implying a +167.9% move over the next 12 months. The stock is currently near its 52-week low of $6.52, remaining 31.6% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $74.27M↑ | $58.30M↑ | $57.58M↑ | $49.50M↑ | $39.50M |
| Gross Profit | $59.18M↑ | $46.30M↓ | $49.94M↑ | $43.31M↑ | $34.47M |
| Operating Income | -$3.96M↑ | -$15.48M↓ | -$5.93M↑ | -$15.27M↑ | -$59.92M |
| Net Income | -$17.58M↑ | -$30.37M↓ | -$21.15M↑ | -$29.97M↑ | -$75.81M |
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment...